Multiple Etiology Dementias: Determine impact of cognitive screening in midlife (Milestone 9.N)
To Be Initiated
Timeline Start - End2022 - 2028
Research Implementation AreaBiomarkers
AD-Related Dementias Focus
Evaluate the benefits, burdens, and harms of screening for cognitive impairment in older adults in the absence of a patient, care partner or clinician report of cognitive, behavioral, or functional changes.
- At least one real-world clinical practice study to determine the benefits, burdens, and harms of screening for cognitive impairment including dementia in older adults. This trial is to be powered to answer the question in at least two populations that experience health disparities.
Summary of Key Accomplishments
This milestone has yet to be initiated. Accomplishments are forthcoming.
The key accomplishments summary is current as of July 2022.
- RFA-NS-22-009: Detecting Cognitive Impairment, Including Dementia, in Primary Care and Other Everyday Clinical Settings for the General Public and Health Equity, Pragmatic Clinical Trials (U01 Clinical Trial Required)
Research Programs and Resources
- ADRD Summit 2016: Multiple Etiology Dementias (MED) Focus Area 3: Determining the Role for Screening for Cognitive Dysfunction, Milestone 6
- ADRD Summit 2022: Multiple Etiology Dementias (MED) Milestone 2, Priority 4